PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22678977-1 2012 Xanthine dehydrogenase (XDH), also known as xanthine oxidoreductase (XOR), has long been recognized as the key enzyme in the catabolism of purines, oxidizing hypoxanthine into xanthine and then xanthine into uric acid. Purines 139-146 xanthine dehydrogenase Homo sapiens 0-22 22678977-1 2012 Xanthine dehydrogenase (XDH), also known as xanthine oxidoreductase (XOR), has long been recognized as the key enzyme in the catabolism of purines, oxidizing hypoxanthine into xanthine and then xanthine into uric acid. Purines 139-146 xanthine dehydrogenase Homo sapiens 24-27 22678977-1 2012 Xanthine dehydrogenase (XDH), also known as xanthine oxidoreductase (XOR), has long been recognized as the key enzyme in the catabolism of purines, oxidizing hypoxanthine into xanthine and then xanthine into uric acid. Purines 139-146 xanthine dehydrogenase Homo sapiens 44-67 22678977-1 2012 Xanthine dehydrogenase (XDH), also known as xanthine oxidoreductase (XOR), has long been recognized as the key enzyme in the catabolism of purines, oxidizing hypoxanthine into xanthine and then xanthine into uric acid. Purines 139-146 xanthine dehydrogenase Homo sapiens 69-72 10604966-1 2000 Xanthine oxidoreductase (XOR) is a mammalian enzyme that possesses a series of redox centers, which use either NAD(+) or molecular oxygen for oxidation of the purines xanthine and hypoxanthine to uric acid. Purines 159-166 xanthine dehydrogenase Homo sapiens 0-23 15451061-1 2004 Xanthine oxidoreductase (XOR) is a widely distributed enzyme, involved in the metabolism of purines, which generates superoxide and is thought to be involved in free radical-generated tissue injury. Purines 92-99 xanthine dehydrogenase Homo sapiens 0-23 15451061-1 2004 Xanthine oxidoreductase (XOR) is a widely distributed enzyme, involved in the metabolism of purines, which generates superoxide and is thought to be involved in free radical-generated tissue injury. Purines 92-99 xanthine dehydrogenase Homo sapiens 25-28 12578558-9 2003 Xanthine oxidoreductase is the key enzyme in the catabolism of purines, although recent data suggest that the physiological function of this enzyme is more complex than previously assumed. Purines 63-70 xanthine dehydrogenase Homo sapiens 0-23 10604966-1 2000 Xanthine oxidoreductase (XOR) is a mammalian enzyme that possesses a series of redox centers, which use either NAD(+) or molecular oxygen for oxidation of the purines xanthine and hypoxanthine to uric acid. Purines 159-166 xanthine dehydrogenase Homo sapiens 25-28 7649415-3 1995 Xanthine oxidase and xanthine dehydrogenase are enzymes involved in the metabolism of purines and pyrimidines in various organisms. Purines 86-93 xanthine dehydrogenase Homo sapiens 21-43 8661045-1 1996 Xanthine dehydrogenase (XDH, EC 1.1.1.204) is a rate-limiting enzyme in the oxidative metabolism of purines and is thought to play a key role in a variety of pathophysiologic processes including ischemiasolidusreperfusion injury, viral pneumonia, and renal failure. Purines 100-107 xanthine dehydrogenase Homo sapiens 0-22 8661045-1 1996 Xanthine dehydrogenase (XDH, EC 1.1.1.204) is a rate-limiting enzyme in the oxidative metabolism of purines and is thought to play a key role in a variety of pathophysiologic processes including ischemiasolidusreperfusion injury, viral pneumonia, and renal failure. Purines 100-107 xanthine dehydrogenase Homo sapiens 24-27 35154100-3 2022 This study aims to explore whether exogenous purines are responsible for increased XOR expression and activity. Purines 45-52 xanthine dehydrogenase Homo sapiens 83-86 7829092-1 1994 Xanthine dehydrogenase (XDH, EC 1.1.1.204) oxidizes a variety of purines, pterins, and other heterogenic nitrogen compounds, serving as a rate-limiting enzyme in nucleic acid degradation. Purines 65-72 xanthine dehydrogenase Homo sapiens 0-22 7829092-1 1994 Xanthine dehydrogenase (XDH, EC 1.1.1.204) oxidizes a variety of purines, pterins, and other heterogenic nitrogen compounds, serving as a rate-limiting enzyme in nucleic acid degradation. Purines 65-72 xanthine dehydrogenase Homo sapiens 24-27 8135849-1 1994 Xanthine dehydrogenase (XDH, EC 1.1.1.204) is a molybdenum iron-sulphur flavin hydroxylase which oxidizes a variety of purines, pterins and other heterogenic nitrogen compounds, serving as a rate-limiting enzyme in nucleic acid degradation. Purines 119-126 xanthine dehydrogenase Homo sapiens 0-22 8135849-1 1994 Xanthine dehydrogenase (XDH, EC 1.1.1.204) is a molybdenum iron-sulphur flavin hydroxylase which oxidizes a variety of purines, pterins and other heterogenic nitrogen compounds, serving as a rate-limiting enzyme in nucleic acid degradation. Purines 119-126 xanthine dehydrogenase Homo sapiens 24-27 34496841-1 2021 BACKGROUND: Xanthine dehydrogenase (XDH) is a critical enzyme involved in the oxidative metabolism of purines, pterin and aldehydes and a central component of the innate immune system. Purines 102-109 xanthine dehydrogenase Homo sapiens 12-34 34496841-1 2021 BACKGROUND: Xanthine dehydrogenase (XDH) is a critical enzyme involved in the oxidative metabolism of purines, pterin and aldehydes and a central component of the innate immune system. Purines 102-109 xanthine dehydrogenase Homo sapiens 36-39 35042470-1 2022 BACKGROUND: Xanthine oxidoreductase (XOR) is a hydroxylase enzyme involved in the metabolism of purines. Purines 96-103 xanthine dehydrogenase Homo sapiens 12-35 35042470-1 2022 BACKGROUND: Xanthine oxidoreductase (XOR) is a hydroxylase enzyme involved in the metabolism of purines. Purines 96-103 xanthine dehydrogenase Homo sapiens 37-40 31955828-2 2020 Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine metabolism and is believed to play important roles in coronary atherosclerosis. Purines 59-65 xanthine dehydrogenase Homo sapiens 0-23 31955828-2 2020 Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine metabolism and is believed to play important roles in coronary atherosclerosis. Purines 59-65 xanthine dehydrogenase Homo sapiens 25-28 30837873-10 2019 Recent clinical studies indicated that treatment with xanthine oxidoreductase inhibitors plus inosine had the strongest impact for increasing the pool of salvageable purines and leading to increased ATP levels in humans, thereby suggesting that this combination is more beneficial than a xanthine oxidoreductase inhibitor alone to treat disorders with ATP deficiency. Purines 166-173 xanthine dehydrogenase Homo sapiens 54-77